Blog

November marks both National Caregivers and Alzheimer’s Awareness months, recognizing those with Alzheimer’s disease (AD) and their families and caregivers who play a significant role caring for people with this progressive brain disease.  SYNAPS Dx (SDx) honors those experiencing AD and the people who care for them not only during November, but also throughout the entire year.  In the …

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the publication of “Morphometric imaging biomarker identifies Alzheimer’s disease even among mixed dementia patients” in Scientific Reports. “Up until now, there have been no autopsy-validated tests shown to accurately …

SYNAPS Dx is taking this opportunity to raise awareness about the significant progress in accurately diagnosing Alzheimer’s disease (AD). Introducing An Alternative Approach SYNAPS Dx recently presented some exciting new data for the DISCERN™  test at the 2022 Alzheimer’s Association International Conference (AAIC). DISCERN is a diagnostic skin test that assesses the factors directly related to the formation of synaptic connections …

SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce the opening of a new, high-tech lab at the North Bethesda, MD Greencourt Innovation Center (GIC) for the national launch of DISCERN™, a minimally invasive diagnostic test to identify …

A significant barrier in Alzheimer’s Disease (AD) research for decades has been the inability to identify AD in people recently diagnosed with dementia and to distinguish AD from other forms of dementia. But as presented at the 2022 Alzheimer’s Association International Conference (AAIC) July 31-August 4, data have been presented to address that barrier. SYNAPS …

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), has released data on the performance of the Morphometric Imaging (MI) assay of the DISCERN test at the Alzheimer’s Association International Conference (AAIC), July 31 – Aug. 4, 2022, San Diego. …

ROCKVILLE, Md.–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce its upcoming presentation of “Autopsy-Confirmed Minimally Invasive Biomarker Identifies Alzheimer’s Disease even in the Presence of Co-Morbid Pathologies” at the Alzheimer’s Association International Conference (AAIC), July 31 …

DALLAS–(BUSINESS WIRE)–SYNAPS Dx (SDx), a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease (AD), is pleased to announce that physicians in the Dallas/Fort Worth (DFW) areas will be among the first in the country to offer area residents access to DISCERN™, a minimally invasive diagnostic test. …

The Longest Day of the year, or summer solstice, happens on June 21, 2022. For this reason, the Alzheimer’s Association chose this day to raise awareness across the world about fighting the darkness of Alzheimer’s disease (AD) through fundraising.  To shine a light on the physician burden of managing the AD journey for patients, SYNAPS Dx points …

SYNAPS Dx is pleased to join other leading health organizations and individuals to help raise awareness of the value of accurate, early diagnosis of Alzheimer’s Disease (AD) during June, Alzheimer’s & Brain Awareness Month. This important event shines a light on brain disorders, including AD as well as other dementias, as a major public health issue. Today, …